4DMedical Ltd
4DMedical Limited is a medical technology company that creates and deploys software-based cardiothoracic imaging technology integrating both algorithms and artificial intelligence.
The business
4DMedical Limited is a medical technology company that creates and deploys software-based cardiothoracic imaging technology integrating both algorithms and artificial intelligence. The Company's software platform delivers quantitative insights from routine clinical imaging to help clinicians assess lung function and cardiopulmonary disease. It provides thoracic imaging that enhances physician diagnoses and management of respiratory conditions. Its products include CT:VQ-Non-Contrast Ventilation-Perfusion, CAC-Coronary Artery Calcification, CT LVAS-Lung Ventilation Analysis, IQ-UIP-Early IPF Detection, LDAf-Functional Lung Density Analysis, LDAi-Lung Density Analysis – Inspiration, LTA-Lung Texture Analysis, PHA-Pulmonary Hypertension Assessment, XV LVAS-Lung Ventilation Analysis, and Companion Imaging. The CT:VQ is a non-contrast post-processing technology that transforms routine, chest computed tomographies (CTs) into quantitative, lobar ventilation (V) and perfusion (Q) maps.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
4DMedical Extends Imaging Technology into Public Hospitals and National Screening Network
4DMedical (ASX: 4DX) has secured three significant agreements to expand the reach of its lung health imaging technology. In Australia, 4DMedical has locked in a multi-year deal with Spectrum Medical Imaging to support the National Lung Cancer Screening Program. The company will also launch a Brazilian lung screening program with a leading pharmaceutical partner, while […]
4DMedical Secures US Medicare Reimbursement Approval for CT:VQ Imaging Software
4DMedical (ASX: 4DX) has received reimbursement approval from the US Centers for Medicare & Medicaid Services (CMS) for its CT:VQ lung imaging platform. The decision follows Food and Drug Administration (FDA) clearance granted last week, aligning regulatory authorisation with a defined payment structure. Together, the approvals clear the path for commercial rollout of the software […]
4DMedical Gains FDA Clearance For Groundbreaking CT:VQ Imaging Software
4DMedical (ASX: 4DX) has received United States Food and Drug Administration (FDA) clearance for its CT:VQ software, marking a major milestone in respiratory diagnostics. The technology is the world’s first non-contrast CT-based ventilation-perfusion tool to replace nuclear medicine scans currently used to assess airflow and blood flow in the lungs. The clearance opens a potential […]
4DMedical analytical software to be used by industry partners to help advance new lung disease therapies
4DMedical (ASX: 4DX) will lend its ground-breaking analytical software to two industry partners working to bring new lung disease therapies to market. US-based SMS Biotech will use the company’s suite of software tools for a trial of its novel human stem cell therapy for the treatment of chronic obstructive pulmonary disease (COPD) and an undisclosed […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.